We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$498M
AUM Growth
+$258M
Cap. Flow
+$49.1M
Cap. Flow %
9.86%
Top 10 Hldgs %
69.52%
Holding
145
New
57
Increased
20
Reduced
22
Closed
41

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$31.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$6.99M
3
MRNA icon
Moderna
MRNA
+$3.94M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$3.78M
5
MTVA
MetaVia Inc
MTVA
+$3.18M

Top Sells

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$2.89M
2
ENLV icon
Enlivex Ltd
ENLV
+$2.31M
3
NOVN
Novan, Inc. Common Stock
NOVN
+$2.11M
4
OTLK icon
Outlook Therapeutics
OTLK
+$1.94M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 11.32%
2 Industrials 0.26%
3 Technology 0.12%
4 Consumer Discretionary 0.09%
5 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RKDA icon
76
Arcadia Biosciences
RKDA
$1.37M
$224K 0.05%
+1,490
New +$232K
ALT icon
77
CALL
Altimmune
ALT
$581M
$202K 0.04%
+189
New +$1.04K
BXRX
78
PUT
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
– –
0
– –
RKTO
79
Rocket One Inc
RKTO
$17.4M
$177K 0.04%
+2,747
New +$215K
XWEL icon
80
PUT
XWELL
XWEL
$8.87M
$141K 0.03%
+17
New +$893
MDGSW
81
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
$123K 0.02%
585,859
-421,585
-42% -$145K
MARK
82
PUT
DELISTED
Remark Holdings, Inc.
MARK
$97K 0.02%
+41
New +$631
BNTC icon
83
Benitec Biopharma
BNTC
$408M
$94K 0.02%
698
-149
-18% -$20.1K
EFOI icon
84
PUT
Energy Focus
EFOI
$17.7M
$83K 0.02%
+17
New +$434
PALI icon
85
Palisade Bio
PALI
$351M
$83K 0.02%
26
– –
MARK
86
DELISTED
Remark Holdings, Inc.
MARK
$80K 0.02%
+3,395
New +$52.2K
RDGT
87
Ridgetech Inc
RDGT
$1.04M
$69K 0.01%
+1
New +$76K
ATXS
88
CALL
DELISTED
Astria Therapeutics
ATXS
$65K 0.01%
+17
New +$605
ENLV icon
89
Enlivex Ltd
ENLV
$37.7M
$65K 0.01%
862
-28,850
-97% -$2.31M
IMNN icon
90
PUT
Imunon
IMNN
$6.43M
$54K 0.01%
+1
New +$434
INO icon
91
Inovio Pharmaceuticals
INO
$84.7M
$54K 0.01%
+167
New +$26.8K
ASXC
92
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$43K 0.01%
+794
New +$383
TEUM
93
DELISTED
Pareteum Corporation
TEUM
$35K 0.01%
56,757
-515,514
-90% -$284K
LMFA
94
DELISTED
LM Funding America
LMFA
$34K 0.01%
+33
New +$22.5K
LFWD icon
95
ReWalk Robotics
LFWD
$19.6M
$34K 0.01%
227
-2,508
-92% -$262K
PTE
96
PUT
DELISTED
PolarityTE, Inc. Common Stock
PTE
$25K 0.01%
+8
New +$213
NSPR icon
97
InspireMD
NSPR
$32.1M
$22K ﹤0.01%
3,220
+2,484
+338% +$25.2K
PULM icon
98
Pulmatrix
PULM
$6.14M
$21K ﹤0.01%
+597
New +$18.9K
LPCN icon
99
Lipocine
LPCN
$17.6M
$18K ﹤0.01%
+850
New +$11K
LPCN icon
100
PUT
Lipocine
LPCN
$17.6M
$13K ﹤0.01%
+6
New +$78
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sabby Management held 145 positions worth $498M, up 107% from $241M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management deployed $49.1M of net new capital in Q2 2020, opening 57 new positions and adding to 20 existing holdings. Its largest new stake was Biogen: 103,902 shares worth $27.8M.

By sector, the portfolio is most concentrated in Healthcare at 11% of assets, up from 7.3% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Enlivex Ltd, an estimated $2.31M trimmed.

  • Sabby Management's largest Q2 2020 buy was Biogen: 103,902 shares worth $27.8M.
  • Sabby Management added most to State Street Health Care Select Sector SPDR ETF in Q2 2020, an estimated $6.99M increase.
  • Sabby Management's biggest Q2 2020 reduction was Enlivex Ltd, cutting an estimated $2.31M.
  • Sabby Management fully exited SPDR Gold Trust in Q2 2020, selling an estimated $2.89M.
  • Sabby Management's ten largest holdings make up 70% of its $498M portfolio in Q2 2020.
  • Sabby Management opened 57 new positions and closed 41 in Q2 2020.
  • Sabby Management's portfolio value rose 107% quarter-over-quarter to $498M.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.